A UK doctor who authored a paper about an osteoporosis drug is to face a General Medical Council hearing over accusations that he falsely declared that he had seen all the data, the BMJ reports (2009;339:b3990). Richard Eastell was research director in Sheffield when the study was submitted to the Journal of Bone and Mineral Research. The university carried out measurements on blood and urine samples that had been taken during trials of Procter & Gamble’s osteoporosis drug risedronate. The data were provided to Procter & Gamble, which carried out analyses, and only these were sent back for interpretation.
Comments